Catalyst
Slingshot members are tracking this event:
Ariad's (ARIA) New Drug Application for Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Accepted for Review by FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARIA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 31, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
New Drug Application, Nda, Brigatinib, Alk-positive, Non-small Cell Lung Cancer, Accepted For Review
